Thrombospondin-1 inhibits ADAMTS13 activity in sickle cell disease

• Enrico M. Novelli,
• Gregory J. Kato,
• Mariana E. Hildesheim,
• Suchitra Barge,
• Michael P. Meyer,
• Jay Lozier,
• Andrea Cortese Hassett,
• Margaret V. Ragni,
• Jeffrey S. Isenberg,
• Mark T. Gladwin

Affiliations

Enrico M. Novelli

Vascular Medicine Institute, Division of Hematology/Oncology, University of Pittsburgh, Pittsburgh, PA, USA

Gregory J. Kato

Sickle Cell Vascular Disease Section, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA

Mariana E. Hildesheim

Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, USA

Suchitra Barge

Vascular Medicine Institute, Division of Pulmonary, Allergy, Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA

Michael P. Meyer

ITXM-Diagnostics, Pittsburgh, PA, USA

Jay Lozier

Sickle Cell Vascular Disease Section, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA

Andrea Cortese Hassett

ITXM-Diagnostics, Pittsburgh, PA, USA

Margaret V. Ragni

Vascular Medicine Institute, Division of Hematology/Oncology, University of Pittsburgh, Pittsburgh, PA, USA

Jeffrey S. Isenberg

Vascular Medicine Institute, Division of Pulmonary, Allergy, Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA

Mark T. Gladwin

Vascular Medicine Institute, Division of Pulmonary, Allergy, Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA